^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Cereblon modulator

    Related drugs:
    1d
    A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3) (clinicaltrials.gov)
    P1/2, N=85, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive • ALK negative
    |
    golcadomide (CC-99282)
    22d
    A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) (clinicaltrials.gov)
    P3, N=525, Active, not recruiting, Bristol-Myers Squibb | Trial primary completion date: Feb 2026 --> Jul 2026
    Trial primary completion date
    |
    carfilzomib • mezigdomide (CC-92480)
    1m
    CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma (clinicaltrials.gov)
    P1, N=18, Recruiting, Nathan Denlinger | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    clonoSEQ
    |
    Rituxan (rituximab) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar) • golcadomide (CC-99282)
    1m
    CA057-001: A trial to determine the safety and effectiveness of CC-92480 in combination with bortezomib and dexamethasone as compared to pomalidomide in combination with bortezomib and dexamethasone in people who have Multiple Myeloma that is not responsive after treatment or has returned after a period of treatment. (2023-509859-13-00`2021-001957-30)
    P2/3, N=322, Active, not recruiting, Celgene Corp. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    bortezomib • pomalidomide • mezigdomide (CC-92480) • dexamethasone injection
    2ms
    CA057-1040: Phase 1b/2a Study to Evaluate Mezigdomide in Combination with Elranatamab in Relapsed and/or Refractory Multiple Myeloma (2025-522090-11-00)
    P1/2, N=24, Recruiting, Celgene Corp.
    New P1/2 trial
    |
    dexamethasone • Elrexfio (elranatamab-bcmm) • mezigdomide (CC-92480)
    2ms
    GOLSEEK-1: Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma (clinicaltrials.gov)
    P3, N=850, Active, not recruiting, Celgene | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • golcadomide (CC-99282)
    2ms
    A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas (clinicaltrials.gov)
    P1/2, N=49, Recruiting, The Lymphoma Academic Research Organisation | Not yet recruiting --> Recruiting
    Enrollment open
    |
    azacitidine • golcadomide (CC-99282) • roginolisib (IOA-244)
    2ms
    A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) (clinicaltrials.gov)
    P3, N=525, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    carfilzomib • mezigdomide (CC-92480)
    2ms
    CC-92480-MM-001: A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (clinicaltrials.gov)
    P1/2, N=200, Terminated, Celgene | Trial completion date: Jan 2028 --> Oct 2025 | Active, not recruiting --> Terminated; Business objectives have changed
    Trial completion date • Trial termination
    |
    dexamethasone • mezigdomide (CC-92480)
    2ms
    Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies (clinicaltrials.gov)
    P1, N=27, Recruiting, Abdullah Khan | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date • IO biomarker
    |
    IKZF1 (IKAROS Family Zinc Finger 1) • CRBN (Cereblon)
    |
    Empliciti (elotuzumab) • Hemady (dexamethasone tablets) • mezigdomide (CC-92480) • dexamethasone injection
    2ms
    Study to Assess Drug Levels and Safety of Golcadomide (BMS-986369) in Healthy Participants and Participants With Different Degrees of Hepatic Impairment (clinicaltrials.gov)
    P1, N=29, Completed, Celgene | Recruiting --> Completed
    Trial completion
    |
    golcadomide (CC-99282)
    3ms
    Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, Massachusetts General Hospital
    New P1 trial
    |
    FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1) • KMT2A (Lysine Methyltransferase 2A)
    |
    FLT3-ITD mutation • NPM1 mutation • KMT2A rearrangement
    |
    Komzifti (ziftomenib) • mezigdomide (CC-92480)